ArticleJournal of the American Society of Hypertension : JASH2014
Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.
Article in Journal of the American Society of Hypertension : JASH, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement.Journal of human hypertension · 2025Guideline
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.Hypertension (Dallas, Tex. : 1979) · 2018Guideline
- Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering.Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension.Journal of the American Society of Hypertension : JASH · 2016Trial
- Lifestyle modification for resistant hypertension: The TRIUMPH randomized clinical trial.American heart journal · 2015Trial
- Proteomic markers associated with blood pressure, hypertension, and treatment-resistant hypertension.American heart journal plus : cardiology research and practice · 2026Article
- Unilateral Renal Denervation for Refractory Hypertension in Aortic Dissection.JACC. Case reports · 2026Article
- What renal denervation registries reveal about resistant hypertension: sex-specific phenotypes, residual risk, and lessons beyond blood pressure.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Associations of 24-Hour Urinary Sodium, Potassium Excretion and Sodium-to-Potassium Ratio With Longitudinal Home Blood Pressure Control in Patients With Apparent Treatment-Resistant Hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2026Observational
- A novel laparoscopic renal denervation system in a preclinical swine model.Scientific reports · 2026Article
- Incidence of Adrenal Masses Eventually Discovered in Patients Screened for Primary Aldosteronism.The Journal of clinical endocrinology and metabolism · 2026Article
- The Role of Mineralocorticoid Receptors in the Treatment of Primary Hypertension.Current hypertension reports · 2026Review
- Fixed-dose combinationFrontiers in pharmacology · 2026Article
- Incidence and prognosis of apparent-treatment resistant hypertension: a multi-state analysis using real world evidence.Clinical hypertension · 2026Article
- Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension.Cardiovascular diabetology · 2025Observational
- Association between the urinary sodium-to-potassium ratio and apparent treatment-resistant hypertension in Japanese patients with non-dialysis dependent chronic kidney disease: the Fukuoka Kidney disease Registry study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Endothelin Receptor Antagonists for the Treatment of Hypertension: Recent Data from Clinical Trials and Implementation Approach.Current cardiology reports · 2025Review
- Predictive Factors of Apparent Treatment Resistant Hypertension Among Patients With Hypertension Identified Using Electronic Health Records.Journal of general internal medicine · 2025Article
- Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program.Journal of the American Medical Informatics Association : JAMIA · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Apparent treatment-resistant hypertension (aTRH) is defined as uncontrolled hypertension despite the use of three or more antihypertensive medication classes or controlled hypertension while treated with four or more antihypertensive medication classes. We evaluated the association of aTRH with incident stroke, coronary heart disease (CHD), and all-cause mortality. Participants from the population-based REasons for Geographic And Racial Differences in Stroke (REGARDS) Study treated for hypertension with aTRH (n = 2043) and without aTRH (n = 12,479) were included. aTRH was further categorized as controlled aTRH (≥4 medication classes and controlled hypertension) and uncontrolled aTRH (≥3 medication classes and uncontrolled hypertension). Over a median of 5.9, 4.4, and 6.0 years of follow-up, the multivariable adjusted hazard ratio for stroke, CHD, and all-cause mortality associated with aTRH versus no aTRH was 1.25 (0.94-1.65), 1.69 (1.27-2.24), and 1.29 (1.14-1.46), respectively. Compared with controlled aTRH, uncontrolled aTRH was associated with CHD (hazard ratio, 2.33; 95% confidence interval, 1.21-4.48), but not stroke or mortality. Comparing controlled aTRH with no aTRH, risk of stroke, CHD, and all-cause mortality was not elevated. aTRH was associated with an increased risk for coronary heart disease and all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.